Covid vaccine developer CureVac shores up C-suite as it heads toward IPO

Local Covid-19 drugmaker CureVac has firmed up its executive team in advance of its much-anticipated IPO.   CureVac, which is based in Germany with U.S. headquarters in Boston, announced Tuesday that Dr. Franz-Werner Haas will become its permanent CEO. He stepped into the role on a temporary basis in March after a week in which CureVac went through two chief executives.  The company has also lured I gor Splawski over from the Novartis Institutes for Biomedical Research in Cambridge to serve as…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news